Attention Deficit Hyperactivity Disorder Across the Lifespan: The Child, Adolescent, and Adult

Disease-a-Month

Volumn 53, Issue 2, 2007, Pages 70-131

  Greydanus, Donald E ^a   Pratt, Helen D ^a   Patel, Dilip R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMINO ACID DERIVATIVE; AMITRIPTYLINE; AMPHETAMINE; ANABOLIC AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; CODEINE; DESIPRAMINE; DEXAMPHETAMINE; DIAMORPHINE; DOPAMINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; MORPHINE; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OXYCODONE; PARACETAMOL; PEMOLINE MAGNESIUM; PIMOZIDE; PSYCHOSTIMULANT AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; ACCOMMODATION PARALYSIS; ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; AGITATION; ANGIONEUROTIC EDEMA; ANOREXIA; ANTICHOLINERGIC SYNDROME; ARTICLE; ATRIOVENTRICULAR BLOCK; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLOOD DYSCRASIA; BLOOD PRESSURE; BLURRED VISION; CHILD; CHILDHOOD DISEASE; COGNITIVE THERAPY; COLLEGE STUDENT; CONFUSION; CONSTIPATION; DECREASED APPETITE; DELIRIUM; DENTAL CARIES; DEPRESSION; DERMATITIS; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG INDICATION; DRUG TOLERANCE; DYSPEPSIA; DYSPHORIA; ECG ABNORMALITY; ERECTILE DYSFUNCTION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GILLES DE LA TOURETTE SYNDROME; GLUCOSE TOLERANCE; GROWTH RETARDATION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; HYPERACTIVITY; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LIFESPAN; LIVER TOXICITY; MEDITATION; MOOD CHANGE; MYDRIASIS; NAUSEA; NERVOUSNESS; NOSE CONGESTION; OBSTRUCTIVE JAUNDICE; OCULAR PRURITUS; ORTHOSTATIC HYPOTENSION; PARENT; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PRIAPISM; PSYCHOPHARMACOLOGY; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; PSYCHOTHERAPY; QRS COMPLEX; QT PROLONGATION; RASH; REBOUND; RESPIRATORY FAILURE; RESTLESSNESS; SALIVATION; SEDATION; SEIZURE; SEIZURE THRESHOLD; SIDE EFFECT; SINUS TACHYCARDIA; SKIN IRRITATION; SOCIAL ADAPTATION; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUPPORT GROUP; SYNCOPE; TACHYCARDIA; TIC; TRAINING; TREMOR; URINE RETENTION; URTICARIA; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD BEHAVIOR; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PREVALENCE; PSYCHOTHERAPY; STUDENTS; SUBSTANCE-RELATED DISORDERS;

EID: 33947423993     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2007.01.001     Document Type: Article

References (210)

1. Lin-Dyken D.C., and Wolraich M.L. Attention deficit hyperactivity disorder. In: Greydanus D.E., and Wolraich M. (Eds). Behavioral Pediatrics (1992), Springer-Verlag, New York, NY 167-193
2. Still G. The Coulstonian lectures on some abnormal physical conditions in children. Lecture 1. Lancet (1902) 1008-1012 1077-902, 1163-8
3. Adler L.A., and Chua H.C. Management of ADHD in adults. J Clin Psychiatry 63 Suppl 12 (2002) 29-35
4. Clements S.D. Minimal Brain Dysfunction in Children: Terminology and Identification (1966), US Department of Health, Education, and Welfare, Washington DC
5. Ounsted C. The hyperkinetic syndrome in epileptic children. Lancet II (1955) 3030-3311
6. Dodson W.W. Pharmacotherapy of adult ADHD. JCLP/In Session 61 5 (2005) 589-606
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (4th ed) (2000), American Psychiatric Association, Washington DC 85-93
8. Wood D.R., Reimherr F.W., Wender P.G., et al. Diagnosis and treatment of minimum brain dysfunction in adults. Arch Gen Psychiatry 33 (1976) 1456-1460
9. Wilens T.E., Spencer T.J., and Biederman J. A review of pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Dis 5 4 (2002) 189-202
10. Faraone S.V., Sergeant J., Gillberg C., et al. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2 (2003) 104-113
11. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163 (2006) 716-723
12. Katragadda S., and Schubiner H. ADHD in children, adolescents, and adults. Prim Care Clin Office Pract 34 4 (2007) 111
13. Biederman J., and Farone S.V. Attention-deficit/hyperactivity disorder. Lancet 366 (2005) 237-248
14. Greydanus D.E., and Pratt H.D. Attention deficit hyperactivity disorder. In: Greydanus D.E., Pratt H.D., and Patel D.R. (Eds). Behavioral Pediatrics. (2nd ed) (2006), iUniverse Publishers, Lincoln, NE 107-142
15. Pary R., Lewis S., Matuschka P.R., et al. Attention deficit disorder in adults. Ann Clin Psychiatry 14 2 (2002) 105-111
16. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 57 (2005) 1215-1220
17. Greydanus D.E., and Pratt H.D. Attention deficit/hyperactivity disorder in adolescents. In: Greydanus D.E., Patel D.R., and Pratt H.D. (Eds). Essential Adolescent Medicine (2006), McGraw-Hill Medical Publishers, New York, NY 751-768
18. Faraone S.V., and Khan S.A. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry 67 Suppl 8 (2006) 13-20
19. Wolraich M.L., Felice M.E., and Drotar D. Impulsive/hyperactive or inattentive behaviors. The Classification of Child and Adolescent Mental Diagnosis in Primary Care: Diagnostic and Statistical Manual for Primary Care (DSM-PC) Child and Adolescent Version (1996), American Academy of Pediatrics, Elk Grove Village, IL 91-110
20. Practice Management Information Corporation. International Classification of Diseases. (10th ed) (2004), Practice Management Information Corporation (PMIC), Los Angeles, CA 223-224
21. MacDonald E., and Opipari-Arrigan L. Behavioral assessment. In: Greydanus D.E., Patel D.R., and Pratt H.D. (Eds). Behavioral Pediatrics. (2nd ed) (2006), iUniverse Publishers, Lincoln, NE 651-669
22. Larsen M.A., and Tentis E. Psychometric testing. In: Greydanus D.E., Patel D.R., and Pratt H.D. (Eds). Behavioral Pediatrics. (2nd ed) (2006), iUniverse Publishers, Lincoln, NE 670-702
23. National Institute of Mental Health (NIMH). Attention Deficit Hyperactivity Disorder (2001). http://www.nimh.nih.gov/publicat/helpchild.cfm NIMH, NIH Publication No. 01-4589. Available at: http://www.nimh.nih.gov/publicat/helpchild.cfm.
24. National Institute of Mental Health. NIMH Research on Treatment for Attention Deficit Hyperactivity Disorder (ADHD): The Multimodal Treatment Study: Questions and Answers (2000), NIMH, Washington DC. http://www.nimh.nih.gov/events/mtaqa.cfm Available at: http://www.nimh.nih.gov/events/mtaqa.cfm.
25. National Institute of Health (NIH). Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement Online 1998: Nov 16-18;16(2):1-37.
26. Greydanus D.E., Pratt H.D., Sloane M.A., et al. Attention-deficit/hyperactivity disorder in Children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am 50 (2003) 1049-1092
27. Whalen C.K., and Henker B. Therapies for hyperactive children: Comparisons, combinations, and compromises. J Consult Clin Psychol 59 1 (1991) 126-137
28. Pelham W., and Fabriano G.A. Behavior modification. Child Adolesc Psychiatr Clin N Am 9 3 (2000) 671-688
29. Pelham W.E., Hoza B., Pillow D.R., et al. Effects of methyphenidate and expectancy on children with ADHD: behavior, academic performance, and attributions in a summer treatment program and regular classroom settings. J Consult Clin Psychol 70 (2002) 320-335
30. Reuters Health. ADHD: Kids with Attention Problems More Likely to Wet Bed (2002), U.S. National Library of Medicine, Bethesda, MD. http://www.nlm.nih.gov/medlineplus/news/fullstory10009.html Wednesday, October 23. Available at: http://www.nlm.nih.gov/medlineplus/news/fullstory10009.html.
31. National Institute of Mental Health (NIMH). Attention Deficit Hyperactivity Disorder (1999). http://www.nimh.nih.gov/sciadvances/16.cfm NIMH. NIH Publication No. 96-3572. Available at: http://www.nimh.nih.gov/sciadvances/16.cfm.
32. Hinshaw S.P. Academic underachievement, attention deficits, and aggression: comorbidity and implications for intervention. J Consult Clin Psychol 60 (1992) 893-903
33. Jensen P.S., Hinshaw S.P., Kraemer H.C., et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40 (2001) 147-158
34. Wells K.C., Epstein J.N., Hinshaw S.P., et al. Parenting and family stress treatment outcomes in attention deficit hyperactivity disorder (ADHD): an empirical analysis in the MTA study. J Abnorm Child Psychol 28 (2000) 543-553
35. Wells K.C., Pelham W.E., Kotkin R.A., et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 28 (2000) 483-505
36. Greydanus D.E., Sloane M.A., and Rappley M.D. Psychopharmacology of ADHD in adolescents. Adolesc Med 13 (2002) 599-624
37. Greydanus D.E. Psychopharmacology of ADHD in adolescents: Quo vadis?. Psychiatr Times 20 (2003) 5-9
38. Greydanus D.E., Calles J., and Patel D.R. Attention deficit hyperactivity disorder. Pediatric and Adolescent Psychopharmacology (chapter 4) (2007), Cambridge University Press, Cambridge, England
39. Greenhill L.L. The science of stimulant abuse. Pediatr Ann 35 8 (2006) 552-556
40. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 94 (1937) 577-585
41. Sallee F.R., and Gill H.S. Neuropsychopharmacology III: Psychostimulants. In: Coffey C.E., and Brumback R.A. (Eds). Textbook of Pediatric Neuropsychiatry (chapter 52) (1998), American Psychiatry Press, Washington DC 1351-1372
42. Angold A., Erkanli A., Egger H., et al. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39 (2000) 975-983
43. Lefever G.B., Dawson K.V., and Morrow A.L. The extent of drug therapy for attention-deficit/hyperactivity disorder among children in public schools. Am J Publ Health 89 (1999) 1359-1364
44. Rowland A.S., Umbach D.M., Stalone L., et al. Prevalence of medication treatment for attention-deficit/hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 92 (2002) 221-234
45. Safer D.J., Zito M., and Fine E.M. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98 (1996) 1084
46. Safer D.J., and Malever M. Stimulant treatment in Maryland public schools. Pediatrics 106 (2000) 533-539
47. Cox E.R., Motheral B.R., Henderson R.R., et al. Geographic variation in the prevalence ofstimulant medication among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics 111 (2003) 237-243
48. Zito J.M., Safer D.J., dosReis S., et al. Psychotropic practice patterns for youth. A 10-year perspective. Arch Pediatr Adolesc Med 157 (2003) 17-25
49. Efron D., Hiscock H., Sewell J.R., et al. Prescribing of psychotrophic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 111 (2003) 372-375
50. Rappley M.D., Mullen P.B., Alvarez F.J., et al. Diagnosis of attention-deficit/hyperactivity disorder an use of psychotropic medication in very young children. Arch Ped Adolesc Med 153 (1999) 1039-1045
51. Rappley M.D., Eneli I.U., Mullan P.B., et al. Patterns of psychotropic medication use in very young children with attention-deficit/hyperactivity disorder. Dev Behav Pediatr 23 (2002) 23-30
52. Zito J.M. Five burning questions. Dev Behav Pediatr 23 (2003) S23-S30
53. Dreyer B.P. The diagnosis and management of attention-deficit/hyperactivity disorder in preschool children: the state of our knowledge and practice. Curr Probl Pediatr Adolesc Health Care 36 (2006) 3-30
54. Guevara J., Lozano P., Wickizer T., et al. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics 109 (2002) 733-739
55. American Academy of Pediatrics, and Committee on Quality Improvement. Clinical Practice Guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Subcommittee on Attention-Deficit/Hyperactivity Disorder. Pediatrics 108 (2001) 1033-1044
56. Clarke S.D. ADHD in adolescence. J Adolesc Health l27 (2000) 77-78
57. Ingram S., Hechtman L., and Morgenstern G. Outcomes issues in ADHD-adolescent and adult long-term outcomes. Ment Retard Dev Disabil Res Rev 5 (1999) 243-250
58. Rushton J.L., and Whitmire J.T. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends, 1992 to 1998. Arch Ped Adolesc Med 155 (2001) 560-565
59. Hechtman L., Weiss G., and Perlmanm T. Young adults outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry 23 (1984) 261-269
60. Solanto M.V., Arnsten A.F.T., and Castellanos F.X. The neuroscience of stimulant drug action in ADHD. In: Solanto M.V., Arnsten A.F.T., and Castellanos F.X. (Eds). Stimulant Drugs and ADHD (2001), Oxford University Press, London
61. Gainetdinov R.R., Wetsel W.C., Jones S.R., et al. Role of serotonin in the paradoxical calming effect of psychostimulants in hyperactivity. Science 283 (1999) 397-401
62. Zito J., Safer D., dosReis S., et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283 (2000) 1025-1030
63. Ford R.E., Greenhill L.L., and Posner K. Stimulants. In: Martin A., Scahill L., Charney D.S., et al. (Eds). Pediatric Psychopharmacology: Principles and Practice (2003), Oxford University Press, New York, NY 255-263
64. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113 (2004) 762-769
65. Efron D., Jarman F., and Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100 (1997) 662-666
66. Greenhill L.L., Halperin J.M., and Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 38 (1999) 503-528
67. Mannuzza S., Klein R.G., Bonagura N., et al. Hyperactive boys almost grow up: replication of psychiatric status. Arch Gen Psychiatry 48 (1991) 77-83
68. Satterfield J.H., Cantwell D.P., Schell A., et al. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 36 (1979) 212-217
69. Weiss M., and Weiss G. Attention deficit hyperactivity disorder. In: Lewis M. (Ed). Child and Adolescent Psychiatry: A Comprehensive Textbook. (3rd ed) (2002), Lippincott Williams & Wilkins, Philadephia, PA 645-670
70. Miller K.J., and Castellanos F.X. Attention-deficit/hyperactivity disorder. Pediatr Rev 19 (1998) 373-384
71. Kuperman S. Tic disorders in the adolescent. Adolesc Med 13 (2002) 537-551
72. Robertson M.M. The Gilles de la Tourette's syndrome: the current status. Br J Psychiatry 154 (1989) 147-169
73. Varley C.K., Vincent J., Varley P., et al. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medication. Compr Psychiatry 42 (2001) 228-233
74. Freeman R.D. Attention deficit hyperactivity disorder in the presence of Tourette syndrome. Neurol Clin 191 (1997) 411-420
75. Wender E.H. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 22 (2001) 183-189
76. Greydanus D.E., and Van Dyke D.H. Neurologic disorders. In: Greydanus D.E., Patel D.R., and Pratt H.D. (Eds). Essential Adolescent Medicine (2006), McGraw-Hill Medical Publishers, New York, NY 235-279
77. Kuperman S. Tic disorders in children and adolescents. In: Greydanus D.E., and Wolraich M.L. (Eds). Behavioral Pediatrics (1992), Springer-Verlag, New York, NY 451-463
78. Greenhill L.L., Pliszka S., Dulcan M.K., et al. Practice parameter for the use of stimulant medication in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 41 (2002) 26S-49S
79. Jadad A.R., Boyle M., Cunningham C., et al. Treatment of Attention-Deficit/Hyperactivity Disorder. Evidence Report/Technology Assessment No. 11 (1999), Agency for Healthcare Research and Quality, Rockville, MD AHRQ Publ. No. 00-E005
80. Castellanos F.X., Giedd J.N., Elia J., et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36 (1997) 589-596
81. Gadow K.D., Nolan E.E., Sprafkin J., et al. School observation of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr 16 (1995) 167-177
82. Gadow K.D., Sverci J., Sprafkin J., et al. Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52 (1995) 444-455
83. Gadow K.D., Sverd J., Sprafkin J., et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 56 (1999) 330-336
84. Law S.F., and Schachar R.J. Do typical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry 38 (1999) 944-951
85. Jankovic J. Tourette's syndrome. N Engl J Med 345 (2001) 1184-1192
86. Robertson M.M., and Eapen V. Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome. Clin Neuropharmacol 15 (1992) 408-425
87. McDougle C.J., Goodman W.K., and Price L.H. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 55 suppl (1994) 24-31
88. Spencer T., Wilens T., Biederman J., et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52 (1995) 434-443
89. Chappell P.B., Riddle M.A., Schahill L., et al. Guanfacine treatment of comorbid attention-deficit/hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34 (1995) 1140-1146
90. Singer H.S., Brown J., Quaskey S., et al. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95 (1995) 74-81
91. Steingard R., Biderman J., Spencer T., et al. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Amer Acad Child Adolesc Psychiatry 32 (1993) 350-353
92. Michelson D., Faries D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) 1197
93. Spencer T., Biederman J., and Wilens J. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am 46 (1999) 915-927
94. Anderson V.R., and Scott L.J. Methylphenidate transdermal system: in attention deficit hyperactivity disorder in children. Drugs 66 8 (2006) 1117-1126
95. McGough J.J., Wigal S.B., Abikoff H., et al. A randomized, double-blind, placebo-controlled laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Dis 9 (2006) 476-485
96. Transdermal methylphenidate (Daytrana) for ADHD. Mett Lett 48 (2006) 49-51
97. López F.A. ADHD: new pharmacologic treatments on the horizon. J Dev Behav Pediatr 27 (2006) 410-416
98. Greydanus D.E. Psychopharmacology. In: Hofmann A.D., and Greydanus D.E. (Eds). Adolescent Medicine. (3rd ed) (1997), Appleton-Lange, Stamford, CT 874-875
99. Adesman A.R. New medications for treatment of children with attention-deficit/hyperactivity disorder. Review and commentary. Pediatr Ann 31 (2002) 514-522
100. Boughton B. Methylphenidate patch effectively treats ADHD. Pediatr News 37 (2003) 6
101. Swanson J. The SNAP Rating Scale. School-Based Assessments and Interventions for ADD Students (1992), KC Publishing, Irvine, CA
102. American Academy of Pediatrics, Committee on Quality Improvement, and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Practice Guideline. Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105 (2000) 1158-1170
103. Rapoport J.L., Buchsbaun M.S., Zahn T.P., et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 199 (1978) 560-563
104. Pliszka S.R., Crismon L., Hughes C.W., et al. The Texas Children's medication algorithm project: revision of the algorithm for pharmacotherapy of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 6 (2006) 642-657
105. Davis G., and Hendren R.L. What pediatricians should know about adolescent psychiatry. Adolesc Med 3 (1992) 131-145
106. Kemph J.P., Devane C.L., Levin G.M., et al. Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 32 (1993) 577-581
107. Hart-Santora D., and Hart L.L. Clondine in attention deficit hyperactivity disorder. Ann Pharmacother 26 (1992) 37
108. Silver L.B. Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatr Clin North Am 46 (1999) 965-975
109. Connor D.F., Fletcher K.E., and Swanson J.M. A meta-analysis of clonidine for symptoms of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38 (1999) 1551-1559
110. Prince J.B., Wilens T.E., Biederman J., et al. Clonidine for sleep disturbances associated with attention-deficit/hyperactivity disorder; a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 35 (1996) 599-605
111. Pliszka S.R. Comparing the effects of stimulant and non-stimulant agents on catecholamine function: Implications for theories of ADHD. In: Solanto M.V., Arnsten A.F.T., and Castellanos F.X. (Eds). Stimulant Drugs and ADHD (2001), Oxford University Press, London 332-352
112. Blackman J.A., Fang-Samson L., and Gutgesell H. Clonidine and electrocardiograms. Pediatrics 98 (1996) 1223
113. Horrigan J.P., and Barnhill J.L. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5 (1995) 215-223
114. Hunt R.D., Arnsten A.F.T., and Asbell M.D. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34 (1995) 50-54
115. Scahill L. Guanfacine for attention deficit hyperactivity disorder. Am J Psychiatry 158 (2001) 1067-1074
116. Staufer W.B., and Greydanus D.E. Attention-devicit/hyperactivity disorder psychopharmacology for college students. Pediatr Clin North Am 52 (2005) 71-84
117. Clark H.W., and Bizzell A.C. Federal perspective: the abuse of prescription stimulants. Pediatr Ann 35 8 (2006) 595-597
118. Arria A.M., and Wish E.D. Nonmedical use of prescription stimulants among students. Pediatr Ann 35 8 (2006) 557-562
119. Musser C.J., Ahmann P.A., Theye F.W., et al. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 19 3 (1998) 187-192
120. McCabe S.E., Teter C.J., and Boyd C.J. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 39 7 (2004) 1095-1116
121. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 165 8 (2001) 1039-1044
122. Greydanus D.E. Stimulant misuse: strategies to manage a growing problem (2006), ACHA Professional Development Program, Princeton, NJ. http://www.acha.org Available at: www.acha.org.
123. Johnston L.D., O'Malley P.M., and Bachman J.G. Monitoring the Future National Survey Results on Drug Use, 1975-2002. II. College Students and Adults Ages 19-40. NIH publication no. 03-5376 (2003), US Department of Health and Human Services, Washington DC
124. McCabe S.E., Knight J.R., and Teter C.J. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 100 (2005) 96-106
125. Teter C.J., McCabe S.E., Cranford J.A., et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 53 6 (2005) 253-262
126. Hall K.M., Irwin M.M., Bowman K.A., et al. Illicit use of prescribed stimulant medication among college students. J Am Coll Health 53 4 (2005) 167-174
127. Graff Low K., and Gendaszek A.E. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med 7 (2002) 283-287
128. Upadhyaya H.P., Rose K., Wang W., et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 15 5 (2005) 799-809
129. Rimsza M.E., and Moses K.S. Substance abuse on the college campus. Pediatr Clin North Am 52 I (2005) 307-319
130. Kadison R. Getting an edge: use of stimulants and antidepressants in college. N Engl J Med 353 (2005) 1089-1091
131. Greydanus D.E., and Patel D.R. The adolescent and substance abuse: current concepts. Dis Mon 51 7 (2005) 392-431
132. Greydanus D.E., and Patel D.R. The adolescent and substance abuse: current concepts. Curr Probl Pediatr Adolesc Health Care 35 3 (2005) 78-98
133. Wilford B.B., Smith D.E., and Bucher R. Prescription stimulant sales on the internet. Pediatr Ann 35 8 (2006) 575-586
134. Drug Enforcement Administration (DEA). Yearly Aggregate Production Quotas (1990-2000) (2002), Office of Public Affairs, Drug Enforcement Administration, Washington DC
135. Conant-Norville D.O., and Tofler I.R. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete. Clin Sports Med 24 (2005) 829-843
136. Katusic S.K., Barbaresi W.J., Colligan R.C., et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 15 5 (2005) 764-776
137. Wilens T.E., Faraone S.V., Biederman J., et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?. A meta-analytic review of the literature. Pediatrics 111 1 (2003) 179-185
138. Fischer M., and Barkley R.A. Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry 64 Suppl 11 (2003) 19-23
139. Faraone S.V., and Wilens T. Does stimulant treatment lead to substance use disorders?. J Clin Psychiatry 64 Suppl 11 (2003) 9-13
140. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youth with and without ADHD. J Clin Psychiatry 64 Suppl 11 (2003) 3-8
141. Barkley R.A., Fischer M., Smallish L., et al. Does the treatment of attention deficit/hyperactivity disorder with stimulants contribute to drug use/abuse?. A 13-year prospective study. Pediatrics 111 1 (2003) 97-109
142. Mannuzza S., Klein R.G., and Moulton III J.L. Does stimulant treatment place children at risk for adult substance abuse?. A controlled, prospective follow-up study. J Child Adolesc Psychopharmacol 13 3 (2003) 273-282
143. McCabe S.E., and Boyd C.J. Sources of prescription drugs for illicit use. Addict Behav 30 (2005) 1342-1350
144. Williams R.J., Goodale L.A., Shay-Fiddler M.A., et al. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict 13 4 (2004) 381-389
145. Murray J.B. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol 132 (1998) 227-237
146. Luna G.C. Use and abuse of amphetamine-type stimulants in the United States. Pan A J Public Health 9 (2001) 114-122
147. Barrett S.P., Darredeau C., Bordy L.E., et al. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry 50 (2005) 457-461
148. Kollins S.H., MacDonald E.K., and Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68 (2001) 611-627
149. Kapner DA. Infofacts resources: recreational use of Ritalin on college campuses. Available at: http://www.edc.org/hec/pubs/factsheets/ritalin.htm. Accessed September 15, 2005.
150. Croft H.A. Physician handling of prescription stimulants. Pediatr Ann 35 8 (2006) 557-562
151. Schubiner H. Substance abuse in patients with attention-deficit/hyperactivity disorder: therapeutic implications. CNS Drugs 19 8 (2005) 643-655
152. DuPont R.L., and Bensinger P.B. Abuse-resistant drug delivery. Pediatr Ann 35 8 (2006) 587-592
153. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 5 (2005) 525-539
154. Barkley R.A., Fischer M., Fletcher K., et al. Persistence of attention deficit hyperactivity disorder into adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111 (2002) 279-289
155. Weiss M.D., and Weiss J.R. A guide to the treatment of adults with ADHD. J Clin Psychiatry 65 Suppl 3 (2004) 27-37
156. Weiss M., and Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ 168 6 (2003) 715-722
157. Biederman J., Monuteaux M.C., Mick E., et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year follow-up study. Psychol Med 36 2 (2006) 167-179
158. Barkley R.A. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63 Suppl 12 (2002) 10-15
159. Barkley R. Driving impairment in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27 (2004) 23-26
160. Kates N. Attention deficit disorder in adults: management in primary care. Canad Fam Pract 51 (2005) 53-59
161. Spencer T., Biederman J., Wilens T., et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 456-463
162. Connor D.F., Glatt S.J., Lopez I.D., et al. Psychopharmacology and aggression. I. A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41 (2002) 253-261
163. Rapport M.D., and Denny C. Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: is body mass predictive of clinical response?. J Am Acad Child Adolesc Psychiatry 36 (1997) 523-530
164. Wender E.H. Managing stimulant medication for attention-deficit/hyperactivity disorder: an update. Pediatr Rev 23 (2002) 234-236
165. Biederman J., Mick E., Surman E., et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59 9 (2006) 829-835
166. A new long-acting methylphenidate (Concerta). Med Lett 42 (2000) 80-81
167. Swanson J.L., Gupta S., Guinta D., et al. Acute tolerance to methylphenidate in the treatment of attention- deficit/hyperactivity disorder in children. Clin Pharmacol Ther 66 (1999) 295-305
168. Another long-acting methylphenidate (Metadate CD). Med Lett 43 (2001) 83-84
169. Dexmethylphenidate (Focalin) for ADHD. Med Lett 44 (2002) 45-46
170. Johnston C., and Fine S. Methods of evaluating methylphenidate in children with attention-deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol 18 (1993) 717-730
171. Barkley R.A. A Clinical Workbook, Attention-Deficit Hyperactivity Disorder. (2nd ed) (1998), Guilford, New York, NY
172. Markowitz J.S. Drug interactions with stimulant medications. Int Clin Psychopharmacol 14 (1999) 1-18
173. Varley C. Sudden death of a child treated with imipramine. J Child Adolesc Psychopharmacol 10 (2000) 321-325
174. Gross-Tsur V., Manor O., van der Meere J., et al. Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective?. J Pediatr 130 (1997) 670-674
175. Rappley M.D. Safety issues in the use of methylphenidate. Drug Saf 17 (1997) 143-148
176. Nissen S.E. ADHD and cardiovascular risk. N Engl J Med 354 (2006) 1445-1448
177. Wilens T.E., Prince J.B., Spencer T.J., and Biederman J. Stimulants and sudden death: what is a physician to do?. Pediatrics 118 (2006) 1215-1219
178. Anders T., Sharfstein S., Rappley M.D., et al. ADHD drugs and cardiovascular risk. N Engl J Med 354 (2006) 2296-2298
179. Spencer T., Biederman J., Wilens T., et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57 5 (2005) 456-463
180. Generic Drugs. Med Lett 44 (2002) 89-90
181. Adderall and other drugs for attention-deficit/hyperactivity disorder. Med Lett Dr Ther 36 (1994) 109-110
182. Weisler R.H., Biederman J., Spencer T.J., et al. Mixed amphetamine salts extended release inthe treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 11 8 (2006) 625-639
183. Biederman J., Spencer T.J., Wilens T.E., et al. Long-term safety and effectiveness of mixed amphetamine salts with extended release in adults with ADHD. CNS Spectr 10 12 Suppl 20 (2005) 16-25
184. Wilens T.E. Bupropion for attention-deficit/hyperactivity disorder. Am J Psychiatry 158 (2001) 282-288
185. Patel D.R., and Greydanus D.E. Office interventions for adolescent smokers. Adolesc Med 11 (2000) 577-588
186. Spencer T., Biederman J., Steingard R., et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32 (1993) 211
187. Adler L.A., Spencer T.J., Milton D.R., et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 66 3 (2005) 294-299
188. Michelson D., Adler L., Spencer T., et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53 2 (2003) 112-120
189. Atomoxetine (Strattera) for ADHD. Med Lett 45 (2003) 11-12
190. Kratochvil C.J., Heiligenstein J.H., Dittman R., et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatr 41 (2002) 776-784
191. Allen A.J., Spencer T.J., Heiligenstein J.H., et al. Safety and efficacy of atomoxetine for AHDH in two double-blind, placebo-controlled trials. Biol Psychiatry 49 suppl 8 (2001) 32S-33S
192. Wilens T.E., Newcorn J.H., Kratochvil C.J., et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 149 1 (2006) 112-119
193. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: a randomized, placebo-controlled study. Am J Psychiatry 159 (2002) 1896-1901
194. Geller B., Reising D., Leonard H.L., et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 38 (1999) 513-516
195. Prince J.B. Nortriptyline in pediatric ADHD. J Child Adolesc Psychopharmacol 10 (2000) 193-204
196. Wilens T.E., Biederman J., Mick E., et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nervous Mental Dis 48 (1995) 183
197. Brent D.A., and Birmaher B. Adolescent depression. N Engl J Med 347 (2002) 667-671
198. Harvey A., and Preskorn S. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 52 (1995) 783-784
199. Bartels M.G., Varley C.K., Metchell J., et al. Pediatric cardiovascular effects of imipramine and desipramine. J Am Acad Child Adolesc Psychiatry 30 (1991) 100-103
200. Varley C.K. Anxiety disorders in children and adolescents. Pediatr Clin North Am 50 (2003) 530
201. Varley C.K. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs 3 (2001) 613-627
202. Sudden death in children treated with a tricyclic antidepressant. Med Lett 32 (1990) 53
203. Varley C.K., and McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 36 (1997) 390-394
204. Findling R.L., Schwartz M.A., Flannery D.J., et al. Venlafaxine in adults with attention- deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatr 57 (1996) 184
205. Adler L.A., and Chua H.C. Management of ADHD in adults. J Clin Psychiatr 63 suppl 12 (2002) 29-35
206. Chan E., Rappaport L.A., and Kemper K.J. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr 24 (2003) 4-8
207. Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin North Am 46 (1999) 977-992
208. Konofal E., Arnulf I., Lecendreux M., et al. Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol 32 5 (2005) 350-351
209. Barkley R.A. Attention-deficit/hyperactivity disorder. Sci Am 279 3 (1998) 66-71
210. Okie S. ADHD in adults. N Engl J Med 354 25 (2006) 2637-2641